Aspirgillosis is a deadly fungal infection that is a major cause of mortality in patients with impaired immune systems. The current standard of care has been voriconazole due to the favorable side effect profile compared to amphotericin. However, posaconazole may not have there adverse effects and be a reasonable course of therapy. Is voriconazole just just a phase?

Today's episode is sponsored by a special CEimpact FREE Law focused webinar: 

Save your spot - FREE LIVE LAW CE

webinar on April 1st.  SPOTS ARE LIMITED!

https://ceimpact.com/law 

Reference: Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140- 6736(21)00219-1. PMID: 33549194.

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases, Volume 63, Issue 4, 15 August 2016, Pages e1–e60, hMps://doi.org/10.1093/cid/ciw326

CPE details for GameChangers Podcast March 2021

Learning Objective: Develop appropriate treatment of aspergillosis infections based on clinical studies.

0107-0000-21-097-H01-P

0.25 CEU/2.5 Hrs (Knowledge)

Initial Release Date: 03/02/21

Expiration Date: 03/02/24

Additional CPE information is located at https://www.ceimpact.com/podcast

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices